Hematologic Oncology | Specialty

Dr. Chari on Investigational Belantamab Mafodotin Combos in Myeloma

August 20th 2020

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.

Dr. Sekeres on Staging Low- Versus High-Risk MDS

August 19th 2020

Mikkael A. Sekeres, MD, discusses staging patients with myelodysplastic syndromes.

Dr. Ghosh on Differences Among Available BTK Inhibitors in B-Cell Malignancies

August 18th 2020

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

Dr. Pagel on Challenges With ASCT in Relapsed/Refractory DLBCL

August 18th 2020

John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Nowakowski on the Rationale for Reevaluating Enzastaurin in DLBCL

August 18th 2020

Grzegorz S. Nowakowski, MD, discusses the rationale for reevaluating the PCKß inhibitor enzastaurin in diffuse large B-cell lymphoma.

Dr. Wong on the Potential Role of Venetoclax in Relapsed/Refractory AL Amyloidosis

August 18th 2020

Sandy Wong, MD, discusses the potential role of venetoclax in relapsed/refractory light chain amyloidosis.

Tazemetostat Expands Follicular Lymphoma Tool Kit

August 18th 2020

The approval of tazemetostat has expanded the portfolio of treatment options for relapsed/refractory follicular lymphoma, a disease for which new agents are needed because patients do not uniformly derive benefit from available therapies.

Dr. Woyach on the Role of Small Molecule Inhibitors in CLL

August 14th 2020

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.

Tafasitamab/Lenalidomide Combo Induces Impressive Response Rates in Relapsed/Refractory DLBCL

August 14th 2020

Kami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges that future research efforts should address.

Dr. Pagel on the Importance of Screening for Double- and Triple-Hit DLBCL

August 13th 2020

John M. Pagel, MD, PhD, discusses the importance of screening patients for double-hit and triple-hit diffuse large B-cell lymphoma.

FDA Panel Supports Remestemcel-L for Pediatric Steroid-Refractory Acute GVHD

August 13th 2020

The FDA’s Oncologic Drugs Advisory Committee voted 8 to 2 in favor of approving remestemcel-L for the treatment of children with steroid-refractory acute graft-versus-host disease.

FDA Grants Umbralisib Priority Review for Previously Treated MZL

August 13th 2020

The FDA has granted a priority review designation to a new drug application for umbralisib for the treatment of patients with previously treated marginal zone lymphoma who have received at least 1 prior anti-CD20–based treatment.

Dr. Nowakowski on Potential Clinical Implications of the ENGINE Study in DLBCL

August 12th 2020

Grzegorz S. Nowakowski, MD, discusses the potential clinical implications of the ongoing, randomized phase 3 ENGINE study in patients with high-risk Denovo Genomic Marker 1–positive diffuse large B-cell lymphoma.

Dr. Woyach on the Role of Chemoimmunotherapy in CLL

August 11th 2020

Jennifer Woyach, MD, discusses ​the role of chemoimmunotherapy in chronic lymphocytic leukemia.

FDA Approvals Augment Advances Made in the DLBCL Armamentarium

August 11th 2020

John M. Pagel, MD, PhD, discusses current treatment approaches in frontline and relapsed/refractory DLBCL and provides insight on some of the agents that are generating excitement in the relapsed/refractory setting.

Dr. Jacobson on the Interim Analysis of the MZL Cohort in the ZUMA-5 Trial

August 11th 2020

Caron Jacobson, MD, discusses the interim analysis results of the marginal zone lymphoma cohort in the phase 2 ZUMA-5 study with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

ASH Releases Evidence-Based Guidelines for Treating Older Patients With AML

August 10th 2020

The American Society of Hematology has published new evidence-based guidelines to support older patients with acute myeloid leukemia and their health care providers in guiding treatment decisions.

The Future of Multiple Myeloma

August 10th 2020

Targeted Treatment Options in Multiple Myeloma

August 10th 2020

Trials in Relapsed/Refractory Multiple Myeloma

August 10th 2020